May 15, 2023 / 05:30PM GMT
Jason Butler - JMP Securities LLC - Analyst
Thank you, everybody, for joining us again this afternoon at the JMP Securities Life Science Conference. Really excited to be joined next by Halozyme Therapeutics' CEO, Helen Torley. Halozyme obviously is a company we've covered for a long number of years. So, it's been a really great transformation over the last several years. You focused fully on building out the -- focused on the royalty streams and then building upon that with the Antares acquisition.
So, Helen, with that I would just say thank you again for being here and we'll maybe just start with the 30-second high-level overview.
Helen Torley - Halozyme Therapeutics, Inc. - President & CEO
Yeah. For those who are not familiar with Halozyme, we're a profitable biotech company. We have two drug delivery platforms that Jason was referring to: our ENHANZE platform that we license to leading companies to transform their IV drugs into subcu and we also, with the acquisition of Antares, acquired an auto-injector platform.
In addition, the third
Halozyme Therapeutics Inc at JMP Securities Life Sciences Conference Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers